The formation of metastases is driven by the ability of cancer cells to disseminate from the site of the primary tumour to target organs. The process of dissemination is constrained by anatomical features such as the flow of blood and lymph in the circulatory system. We exploit this fact in a stochastic network model of metastasis formation, in which only anatomically feasible routes of dissemination are considered. By fitting this model to two different clinical datasets (tongue & ovarian cancer) we show that incidence data can be modelled using a small number of biologically meaningful parameters. The fitted models reveal site specific rates of dissemination and also allow for patient-specific predictions of metastatic involvement based on primary tumour location and stage. Applied to other data sets this type of model could yield insight about seed-soil effect, and could also be used in a clinical setting to provide personalised predictions about the extent of metastatic spread.
INTRODUCTION
fitting the model to a large autopsy data set [17] . The entries of this transition matrix gives 73 information about rates of dissemination between different organs.
74
Here we build on the work of Newton et al., but with secondary seeding in mind, make 75 modifications which alleviate the problem underdetermination, which plagued their work.
76
In order to parametrise their model they had to assume that the observed patterns of 77 metastasis correspond to a steady-state distribution of the model. We instead make use 78 of primary tumour stage to create a model which is temporal and considerably easier to 79 parametrise.
80
Focusing on two primary tumours we show that our model provides highly accurate 81 estimates of dissemination rates, and crucially allows us to estimate rates between sites, 82 which are inaccessible if one simply analyses incidence data.
83

RESULTS
84
Our aim is to quantify the rate of metastatic spreading by applying a stochastic network 85 model to clinical data. We will consider two different data sets: (i) A cohort of 141 patients 86 diagnosed with tongue cancer where metastases occur in the head and neck region and (ii) 87 data from patients with ovarian cancer obtained from the SEER-database where metastases 88 occur both regionally and to some extent in distant organs. Regional spread typically occurs 89 via the lymphatic system and metastases appear in lymph nodes (LN), whereas distant 90 metastases are mediated by the blood circulatory system and appear in other organs such as 91 the liver or the lung. Although the two processes are different in some respects they also share 92 many commonalities. Firstly, the spread of the disseminated tumour cells is constrained by random variable, and the probability of it being positive depends on the state of the other not consider the size of metastases in this model, since this would require more parameters 107 [18] , and would make it more difficult to fit the model to clinical data. This implies that 108 the state of each site X i is a binary variable taking the value 0 if the site is empty and 1 if 109 it contains a metastasis.
110
Each cancer cell which is disseminated from a site has the same probability of forming a 111 metastasis at a downstream site. Since it is known that filtration rates are high (only 1 in 10 112 000 cells pass through a capillary bed) [8] we assume that CTCs only flow to neighbouring 113 sites, e.g. CTCs released on the venous side of the circulatory system can only give rise to 114 metastases in the lung, since this is the first capillary bed they encounter. This is also a 115 good approximation for lymphatic spread, where the occurence of skip metastases, in which 116 intermediary LNs are negative, is rare [19] . We aggregate the rate of release of CTCs, the 117 survival probability in the circulatory system and the probability of forming a metastases 118 in a downstream site into a single rate parameter, which we call λ, when flow is from the 119 primary tumour, and φ, when flow is from metastatic sites. This parameter then corresponds 120 to the rate at which a downstream site becomes positive given a positive site upstream.
121
We include a temporal dimension into the model by using the primary tumour stage as 122 a proxy for time. This means that we consider the stage as informative about the total 123 number of CTCs that have been disseminated from the initiation of the tumour up until 124 diagnosis. This is of course a crude approximation since it is known that tumour progress 125 at different rates and preferentially disseminate to different sites depending on for example 126 which mutations it harbours [20] . Although tumours might progress at different rates they 127 still have to pass all the intermediary stages, and very rarely regress to a lower stage. Since We now move on to discuss the models specific to tongue cancer and ovarian cancer.
134
The drainage of the lymphatic system in the head and neck area can be described by a The flow between lymph node stations is defined by the rates φ I , φ II and φ III .
Given a primary tumour metastases will eventually form in downstream stations, but the 
152
The fraction of patients with stage t tumour with positive lymph node at station I is then
153
given by
The same procedure is applied to stations II-IV yielding stage-dependent fractions.
155
The fraction p together with 95 % confidence intervals obtained using parametric bootstrap (see Methods).
163
It is worth noting that the rate of dissemination from station I to II are close to zero, we observe an interesting pattern (see fig. 3 ). We see that we either obtain a model with 
Metastasis in ovarian cancer
173
Ovarian cancer has the highest mortality rate of the gynecological cancers and a majority 
186
The data set on ovarian cancer was obtained from the SEER-database (see Methods).
187
As of 2010 SEER contains information about the presence of absence of metastases at 188 diagnosis in liver, lung, brain and bone. The status of regional LNs (including the pelvis 189 and diaphragm) is also available.
190
Given the available data we did not try to model transcoelomic dissemination, and instead rates to constrain the possible dissemination rates in the model.
242
The results presented here could be followed in many interesting directions. For example, type of analysis would make it possible to quantify 'seed-soil' effects, which would appear 246 as a variation in dissemination rates. Further, it would be possible to simulate the effect of 247 treatment, which would reveal potential benefits of treating metastatic sites.
248
From a clinical point of view, this work could be of importance, by contributing to 249 an increased possibility to predict the risk of future regional and/or distant metastases.
250
Especially so in the current era, with new treatment modalities emerging and a current 251 development towards more individualised treatment programs.
252
In conclusion we believe that this framework for analysing metastatic spread, which in-
253
corporates known anatomical constraints and a temporal dimension, allows for novel insights 254 and will hopefully be of assistance to both cancer biologists and clinicians in the future.
255
METHODS
256
Data
257
Tongue cancer. After approval from the the Regional ethical review board in Gothenburg, we collected information about in which lymph node levels (I-V) metastases were present.
266
Only one patient exhibited metastasis in lymph node level V, and therefore this level was • Presence/Absence of metastases in lung (CS-mets at DX-lung)
286
• Presence/Absence of metastases in liver (CS-mets at DX-liver)
287
• Presence/Absence of metastases in bone (CS-mets at DX-bone)
288
• Presence/Absence of metastases in brain (CS-mets at DX-brain)
289
Mathematical model
290
The model consists of N nodes each representing a specific site/organ. To each node we associate a random variable X i (t), i = 1, ..., N , which takes the value 0 at time t if the site is void of metastases and 1 if the site contains one or more metastases. The state of each site evolves according to a continuous-time Markov chain with state space {0, 1} and the rate at which site i becomes positive (transitions from 0 → 1) is given by
where β ij is the rate of CTC flow from site j to i. We assume that once a site has become 291 positive it will remain so for all future times, i.e. the transition rate from 1 → 0 is zero for 292 all sites. The initial condition is X 1 (0) = 1, where 1 is the site of the primary tumour, and
293
X k (0) = 0 for k > 1.
294
Due to the sparseness of the network (most β ij 's are zero), and for notational convenience 295 we denote flow rates from the primary with λ i and flow rates between sites with φ i . We now 296 move on to specify the models for tongue cancer and ovarian cancer respectively.
297
Tongue cancer. We let P i (t) denote the probability that LN station i is negative (i.e. P i (t) = Pr(X i (t) = 0)), where i = I, II, III, IV . Then for station I we have that since Λ I = λ I is a constant, P I (t) obeys the ordinary differential equation
where λ I is the dissemination rate from the primary tumour. This equation, with the initial condition P I (0) = 0 (the station is always negative at tumour initiation), has the solution P I (t) = e −λ I t . The probabilities for the remaining stations can be written
where the dissemination rates are given in fig. 1 . The equation for P II (t) can be solved explicitly to yield P II (t; λ I , λ II , φ I ) = e φ I /λ I −(φ I +λ II )t−φ I e −λ I t /λ I .
For P III (t) and P IV (t) it is not possible to get closed form expression and we therefore have 298 to rely on numerical solutions.
299
To estimate the parameters we make use of a maximum likelihood method. Preferably Pr(lymph node is positive) = Pr(metastasis appeared at t < τ ) = 1 − e −λτ .
On the other hand, the probability of the patient being node negative is simply given by
306
Pr(lymph node is negative) = e −λτ .
If we let M τ denote the total number of patients at stage τ , and N 
which depends on the direct dissemination rate λ I . In order to find the λ I that best fits the 
314
Ovary cancer. Again we let P i (t) denote the probability that site i is negative, where i = LN, lung, liver, bone and brain. P LN (t) obeys the ordinary differential equation
where λ 1 is the dissemination rate from the primary tumour. This equation, with the initial condition P LN (0) = 0 (the LN are always negative at tumour initiation), has the solution P LN (t) = e −λ LN t . The probabilities for the remaining sites can be written dP lung (t) dt = −λ 2 P lung (t) − φ 1 (1 − e −λ 1 t )P lung (t) dP liver (t) dt = −φ 2 P lung (t)P liver (t) dP bone (t) dt = −φ 3 P lung (t)P bone (t), dP brain (t) dt = −φ 4 P lung (t)P brain (t), where the dissemination rates are given in fig. 4 . The equation for P lung (t) can be solved explicitly to yield P lung (t; λ 1 , λ 2 , φ 1 ) = e φ 1 /λ 1 −(φ 1 +λ 2 )t−φ 1 e −λ 1 t /λ 1 .
For the remaining sites it is not possible to get closed form expression and we therefore have 315 to rely on numerical solutions.
316
In order to find the most likely parameters that describe the data we again make use of 317 the maximum likelihood method described above.
318
